Completed PHASE2 INTERVENTIONAL 3-arm NCT00545935

Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso

Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso: RCT in the Frame of the A8 Project of SFB 544

Sponsor: Heidelberg University

Conditions Malaria

Interventions Artesunate-Amodiaquine (AS-AQ) Methylenblue-Amodiaquine (MB-AQ) Methylenblue-Artesunate (MB-AS)

Updated 5 times since 2017 Last updated: Feb 2, 2009 Started: Jul 31, 2007 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Malaria, this trial is completed. The trial is conducted by Heidelberg University and has accumulated 5 data snapshots since 2007. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Heidelberg University

Data source: Heidelberg University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nouna, Burkina Faso